NICE Rejects Vidaza, But Celgene Plans Comparator-Based Appeal
This article was originally published in The Pink Sheet Daily
Executive Summary
Cancer drug is effective but still too expensive even with a 7 percent price cut, NICE concludes.
You may also be interested in...
Celgene Ups Vidaza Discount To Gain Positive NICE Recommendation
U.K. cost-watchdog NICE recommends reimbursement for Celgene's Vidaza after the company offers a steeper discount.
Celgene Ups Vidaza Discount To Gain Positive NICE Recommendation
U.K. cost-watchdog NICE recommends reimbursement for Celgene's Vidaza after the company offers a steeper discount.
Celgene And Three UK Patient Groups Appeal NICE's Rejection Of Vidaza
Myelodysplastic patients want access to a Celgene drug rejected as too expensive by UK's health technology assessor.